




#KeepYourThyroid #DesignedToPredictBenign

### The Thyroid Genetic Classifier to safely forgo unnecessary diagnostic thyroid surgery for indeterminate cytology

Approximately 20% of indeterminate nodules (Bethesda III/IV) are managed through diagnostic surgery, which is the standard approach. After surgery, up to 75% of these nodules are determined to be benign.<sup>1</sup> ThyroidPrint® reclassifies nodules as either benign or suspicious of malignancy, aiding decision-making, avoiding patients to undergo unnecessary surgeries, and reducing healthcare costs.

### ThyroidPrint® clinical pathway in case of thyroid nodule detection

ThyroidPrint® accurately classifies indeterminate thyroid nodules with 95% NPV<sup>2,3</sup>




### ThyroidPrint® Clinical Utility Study reduces unnecessary surgery by 67%<sup>4</sup>

Without ThyroidPrint®



With ThyroidPrint®



**Idylla™  
ThyroidPrint® Assay\*\***

The **first-in-class assay** in kit format  
for indeterminate thyroid nodules  
For Research Use Only, assay currently under development

**Idylla™ ThyroidPrint® Assay\*\***



qPCR of 10 genes  
in a diagnostic kit



Tumor Inflammatory  
microenvironment Genes



Tumor Epithelial  
Genes



Stabilizing Genes



Proprietary  
algorithm analysis



**Unique sample-to-insight seamless workflow**



Scan  
Sample & Cartridge



Insert Sample  
in the Cartridge



Insert Cartridge in the Idylla™ Platform  
and obtain the result within 3 hours

- (1) Haugen et al., 2015 American Thyroid Association Management guidelines for adult patients. *Thyroid*, 2016
- (2) Gonzalez et al., A 10-Genes Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. *Thyroid*, 2017
- (3) Zafero et al., A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology. Two Independent, Multicenter, Prospective Validation Trials. *Thyroid*, 2020
- (4) Olmos et al., ThyroidPrint®: clinical utility for indeterminate thyroid cytology. *End Rel Cancer*, 2023

[thyroidprint.com/wctc](http://thyroidprint.com/wctc)



**GENEPRODX**  
Transforming Precision Medicine



Biocartis NV  
Generaal De Wittelaan 11B  
2800 Mechelen - Belgium  
+32 15 632 888

Follow us on

[www.biocartis.com](http://www.biocartis.com)  
[customerservice@biocartis.com](mailto:customerservice@biocartis.com)

\*ThyroidPrint® LDT currently available as a Laboratory Developed Test in GenezroDx® CAP accredited laboratory in Santiago de Chile (Chile).

\*\*Idylla™ ThyroidPrint® is currently under development and planned to be released as an assay for Research Use Only, not for use in diagnostic procedures.

© Biocartis NV, June 2023. All rights reserved.